18865-48-0
Chemical Structure
Actinomycin X2 (purity≥85%)
Synonym(s): Actinomycin V (purity≥85%)
- CAS No.: 18865-48-0
- Formula:C62H84N12O17
- Molecular Weight:1269.40
IUPAC Name: 2-amino-N1-((6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14,17-hexaoxohexadecahydro-1H-pyrrolo[2,1-i][1]oxa[4,7,10,13]tetraazacyclohexadecin-10-yl)-N9-((6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1]oxa[4,7,10,13]tetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
InChIKey: GQZJMUMSSGCVFS-IRFLANFNSA-N
SMILES: O=C(N[C@H](C(N[C@H](C(C)C)C(N([C@@]([H])(C1)C2=O)CC1=O)=O)=O)[C@@H](C)OC([C@H](C(C)C)N(C)C(CN2C)=O)=O)C(C3=NC4=C(C(N[C@H](C(N[C@H](C(C)C)C(N5[C@@]([H])(CCC5)C6=O)=O)=O)[C@@H](C)OC([C@H](C(C)C)N(C)C(CN6C)=O)=O)=O)C=CC(C)=C4OC3=C7C)=C(N)C7=O
Biological Activity: Actinomycin X2 (Actinomycin V), produced by many Streptomyces sp., shows strong inhibition of MRSA with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Actinomycin X2 (purity≥85%) | 87.99% | Actinomycin X2 (Actinomycin V), produced by many Streptomyces sp., shows strong inhibition of MRSA with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhiyu Chen, et al. Anti-MRSA Activity of Actinomycin X 2 and Collismycin A Produced by Streptomyces globisporusWA5-2-37 From the Intestinal Tract of American Cockroach ( Periplaneta americana). Front Microbiol. 2020 Apr 7;11:555. [Content Brief]
- [2]. Liu J, et al. Apoptosis of human prostate cancer cells induced by marine actinomycin X2 through the mTOR pathway compounded by MiRNA144. Anticancer Drugs. 2016 Mar;27(3):156-63. [Content Brief]
